Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan
Takuto Hara, Kotaro Suzuki, Yasuyoshi Okamura, Koji Chiba, Ryo Sato, Yuto Matsushita, Keita Tamura, Gaku Ishikawa, Atsushi Otsuka, Hideaki Miyake
Topics & Concepts
LenvatinibMedicinePembrolizumabSurgical oncologyRenal cell carcinomaOncologyInternal medicineSafety profileFirst line treatmentAdverse effectGeneral surgeryImmunotherapyChemotherapyCancerThyroid cancerRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersRenal Diseases and Glomerulopathies